Prostate CancerSudden Cardiac DeathClinical OncologyFragility FractureThe article discusses research on the impact of androgen deprivation therapy (ADT) on diabetes and cardiovascular disease in men with prostate cancer. Results revealed that 1,392 ADT users compared with 1,181 nonusers developed incident...
雄激素剥夺疗法(ADT)是治疗转移性前列腺癌的主要方法,而额外的挽救性放疗可以延长区域结节复发患者的缓解期。《Eur Urol》杂志发表了一篇标题为“Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiother...
原文来源: Li JR, Wang SS, Chen CS, Cheng CL, Hung SC, Lin CH, Chiu KY. Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide popul...
heimer ’ s disease News ADT in prostate cancer and risk of Alzheimer ’ s diseaseNews ADT in prostate cancer and risk of Alzheimer ’ s diseaseBagcchi, Sanjeet
mHSPC 患者的新标准治疗方案之一。原文阅读：https://www.urotoday.com/conference-highlights/eau-2024/eau-2024-prostate-cancer/151003-eau-2024-efficacy-and-safety-of-darolutamide-in-combination-with-adt-and-docetaxel-in-european-patients-from-the-phase-3-arasens-trial.html ...
ADT not linked to excess CV mortality in prostate cancer.The article discusses research on the link between androgen-deprivation therapy (ADT) and the risk of cardiovascular (CV) death in men with unfavourable-risk prostate cancer, referencing a study by P. L. Nguyen et al in the December ...
2023年11月02日,哥伦比亚大学爱尔文医学中心的研究人员在Cancer Cell期刊发表了题为:Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer的研究文章。 与其他恶性肿瘤相比,原发性和去势抵抗性前列腺癌(CRPC)的肿瘤微环境(TME)...
Langley RE, et al. Transdermal oestradiol for androgen suppression in prostate cancer: long-termcardiovascularoutcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.Lancet. 2021 Feb 13;397(10274):581-591. ...
[1]Nicholas David James,HannahRush,MatthewGuyNankivell,et al.Transdermal oestradiol(tE2)patches as androgen deprivation therapy(ADT):Efficacy and safety of combining with androgen receptor pathway inhibitors(ARPIs)in metastatic(M1)prostate cancer—Randomised comparison from the STAMPEDE trial platform.ASCO...
"Generally speaking, men who are having postoperative radiotherapy for prostate cancer usually do well and do not develop metastasis in 10 years," said lead author Chris Parker, MD, consultant clinical oncologist at The Royal Marsden NHS Foundation Trust in London, UK. "But the addition of 2 ...